The New WHO Classification of Lung Tumors

Lung Cancer Biomarker Testing Patterns Varied Widely in Japan

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Patient Comment on Mobocertinib for Exon 20

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation